Teva Says Wyeth Patent Deal Doesn't Step On Antitrust Law

Law360, New York (April 9, 2012, 8:47 PM EDT) -- Teva Pharmaceuticals USA Inc. on Friday moved to toss direct purchasers' claims in multiple class actions and individual suits accusing it of conspiring with Wyeth LLC to delay a generic antidepressant's entry into the market, arguing that settling patent litigation with Wyeth didn’t violate antitrust law.

In a series of coordinated class actions and individual suits brought by direct purchasers, Teva maintains it did not enter into a sham settlement with Pfizer Inc. unit Wyeth in order to delay the entry of Effexor XR into the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.